Loading...
XJPX
4977
Market cap132mUSD
Oct 09, Last price  
1,167.00JPY
1D
1.57%
1Q
-11.46%
Jan 2017
57.70%
IPO
142.62%
Name

Nitta Gelatin Inc

Chart & performance

D1W1MN
XJPX:4977 chart
P/E
6.48
P/S
0.56
EPS
180.20
Div yield, %
2.00%
Shrs. gr., 5y
0.08%
Rev. gr., 5y
4.49%
Revenues
38.05b
-1.80%
27,923,134,00027,763,016,00028,772,135,00032,814,056,00031,914,983,00036,885,000,00036,575,000,00037,777,000,00036,464,000,00034,543,000,00030,550,000,00031,783,000,00039,186,000,00040,420,000,00038,745,000,00038,048,000,000
Net income
3.28b
+3.86%
1,051,672,0001,375,869,0001,565,879,000665,490,000610,067,000477,000,000693,000,000-615,000,000989,000,000-694,000,000742,000,000726,000,0001,558,000,000-1,850,000,0003,160,000,0003,282,000,000
CFO
6.48b
+25.06%
1,570,410,000568,211,0002,050,213,000-692,883,0002,074,146,0002,385,000,0001,910,000,0001,419,000,0002,232,000,0001,969,000,0003,509,000,0001,044,000,000-540,000,0004,911,000,0005,183,000,0006,482,000,000
Dividend
Mar 30, 202720 JPY/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Established in Osaka, Japan, in 1918, Nitta Gelatin Inc. is a leading manufacturer and supplier primarily focused on gelatin and collagen products. The company's operations encompass the production and distribution of edible, pharmaceutical, and photographic gelatin, predominantly within the Japanese market. Utilizing raw materials like animal bones and skin, as well as fish scales and skin, they also develop a varied range of collagen-derived products. This includes industrial-grade gelatin for both food and pharmaceutical industries, alongside collagen peptides, which are known for their bioactive and bioregulatory characteristics, produced using proprietary proteolytic technology. Additionally, Nitta Gelatin provides other food ingredients and stabilizers vital for confectionery, desserts, delicatessen items, and chilled foods. They further extend their expertise to the medical field, supplying specialized collagen and medical gelatin to device manufacturers and research institutions for use as biomaterials in applications such as artificial skin and bone.

Key people

Kei Ando
Executive Officer, Chief Director of Administration, Director of System Solutions, Director · since 2025
Yosuke Hiraoka
Executive Officer, Manager of Comprehensive Research Center · since 2024
Arifumi Hirata
Executive Officer, Director of Business Planning · since 2025
Kazuya Nakao
Executive Officer, Director of Internal Sales in Main Sales Unit · since 2024
Yoshihisa Sugimoto
Executive Officer, Chief Director of Sales, Director · since 2025
Takuya Tanaka
Executive Officer, President and Chairman of Subsidiaries · since 2025
Noriyuki Tsuji
Executive Officer, Deputy Chief Director in Main Production Unit, Director of Global Production Control · since 2024
Kazuya Hayashi
Executive Officer, Chief Director of Production, Director · since 2024
Hidenori Takemiya
Executive President, Representative Director · since 2024
Hiromasa Suzuki
Independent Director · since 2022
Hisao Takahashi
Independent Director · since 2024
Yumiko Tanada
Independent Director · since 2025
IPO date
Dec 20, 2011
Employees
1,023
Domiciled in
JP
Incorporated in
JP

Valuation

Title
JPY in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2026‑032025‑032024‑032023‑032022‑032021‑032020‑032019‑032018‑032017‑03
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT